PCT " ANTIBODIES SPECIFIC FOR MMP9" number WO 2016/023972 and WO 2016/023979, published on 18.02.2016.
PCT "ANTIBODIES TO IL-15", number WO 2016/001275 A1, published on 07.01.2016.
An innovation grant received from CTI to develop CALY-001 for Crohn’s disease.
Calypso Biotech SA, Universitätsspital Zürich and Centre Hospitalier Universitaire Vaudois have received a 186 072 CHF grant from the Swiss Commission for Technology and Innovation (CTI).
This contribution is supporting the development of CALY-001, a therapeutic antibody having the potential to treat fistulizing Crohn’s Disease, a severe complication of Crohn’s disease for which no cure exists. This grant, allocated by the CTI, will finance Calypso Biotech's translational studies of CALY-001. Two research laboratories are going to work in parallel. On the one hand, at the Universitätsspital Zürich, Professor Gerhard Rogler, an international expert in intestinal inflammatory diseases (IBD), will conduct the research using blood samples from patientswith Crohn’s disease in order to identify biomarkers of fistulizing disease. On the other hand, at the Centre Hospitalier Universitaires Vaudois, Dr. Dominique Velin, an international expert in intestinal inflammatory disease preclinical investigation, will conduct the research using experimental models to demonstrate in vivo efficacy of CALY-001.
About the CTI: As the Confederation's innovation promotion agency, the Swiss Commission for Technology and Innovation (CTI) lends support to R&D projects, to entrepreneurship as well as to the development of start-up companies in Switzerland. CTI helps to optimise knowledge and technology transfer through the use of national thematic networks. Click here for further information.